Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1−/− mice

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7356-7362

  Bentzien, Frauke ^a   Struman, Ingrid ^b   Martini, Jean François ^a   Martial, Joseph ^b   Weiner, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PROLACTIN DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DNA TRANSFECTION; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ANIMALS; CELL DIVISION; CHICK EMBRYO; COLONIC NEOPLASMS; CULTURE MEDIA, CONDITIONED; GENES, RAG-1; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROLACTIN; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035476272     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. What is the evidence that tumors are angiogenesis dependent?
2. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo
3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
4. Angiogenin antagonists prevent tumor growth in vivo
5. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells
6. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
7. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
8. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
9. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
10. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4
11. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
12. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
13. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients
14. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer
15. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
16. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
17. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor Tnp-470
18. Contribution of angiogenesis to the progression of colon cancer: Possible inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and hepatic metastasis
19. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity
20. Mouse endostatin inhibits the formation of lung and liver metastases
21. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin
22. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells
23. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation
24. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis
25. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules
26. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells
27. Bovine brain and pituitary fibroblast growth factors: Comparison of their abilities to support the proliferation of human and bovine vascular endothelial cells
28. Human prolactin. cDNA structural analysis and evolutionary comparisons
29. Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation
30. Binding of iodinated rat and ovine prolactins to prolactin receptors and to its antibodies
31. 131I-labelled growth hormone of high specific radioactivity
32. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: Activation of plasminogen activator inhibitor 1 expression
33. Protamine is an inhibitor of angiogenesis
34. Rag-1-deficient mice have no mature B and T lymphocytes
35. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
36. IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells
37. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
38. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
39. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis